Edition:
United States

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

194.30USD
30 Nov 2016
Change (% chg)

-- (--)
Prev Close
$194.30
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
932,036
52-wk High
$322.66
52-wk Low
$184.58

Latest Key Developments (Source: Significant Developments)

Allergan has no interest in a Biogen deal - CNBC, citing sources
Wednesday, 3 Aug 2016 09:38am EDT 

:Allergan has no interest in a Biogen deal - CNBC, citing sources.  Full Article

Allergan announces sale of Anda distribution business to Teva
Wednesday, 3 Aug 2016 07:00am EDT 

Allergan Plc : For Q2 of 2016, Anda is expected to contribute approximately $375 million in net revenues excluding sales of Allergan's branded products . For Q2 of 2016, Anda is expected to contribute approximately $0.05 in earnings per share . Allergan announces sale of Anda distribution business to Teva Pharmaceuticals . Allergan Plc says deal valued at $500 million . Anda to be reported as discontinued operations beginning with Q2 2016 earnings report on August 8, 2016 .For full year 2016, Anda is expected to contribute approximately $1.5 billion in third-party net revenue and approximately $0.15 in EPS.  Full Article

Allergan unlikely to pursue Biogen deal- CNBC,citing source
Tuesday, 2 Aug 2016 04:15pm EDT 

: Allergan unlikely to pursue Biogen deal- CNBC,citing source (Bengaluru Newsroom: +1-646-223-8780).  Full Article

Allergan completes divestiture of global generics business to Teva Pharmaceuticals
Tuesday, 2 Aug 2016 12:41pm EDT 

Allergan PLC : Allergan PLC completes divestiture of Global Generics Business to Teva Pharmaceuticals . Company to provide updated guidance as part of Q2 2016 earnings . Plans to commence its previously announced share repurchase program of up to $10 billion of company's common stock in coming days .Company expects to execute an initial $5 billion in open market repurchases over remainder of 2016.  Full Article

Teva gets U.S. FTC clearance for Actavis Generics deal
Wednesday, 27 Jul 2016 02:36pm EDT 

Teva Pharmaceutical Industries Ltd : Teva receives clearance from the U.S. Federal Trade Commission for Actavis Generics acquisition . Has satisfied regulatory approval requirements under purchase agreement to complete acquisition of Actavis Generics .Transaction is expected to close next week.  Full Article

Allergan receives positive opinion for its treatment for IBS-D in adults
Monday, 25 Jul 2016 11:30am EDT 

Allergan Plc : Allergan receives positive opinion for Truberzi® (eluxadoline) for treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults . Truberzi® was generally well tolerated with most common side effects being nausea, constipation, and abdominal pain . Final decision from European Commission on Truberzi is expected within a few months .If approved, anticipate launching Truberzi in Europe during 2017, following negotiations with relevant national payer,reimbursement groups.  Full Article

Allergan and Adamas says FDA approved new, expanded label for Namzaric
Tuesday, 19 Jul 2016 07:59am EDT 

Allergan Plc : In addition to two currently available dosage strengths, two new Namzaric dosage strengths will be available in pharmacies in September. . Allergan and Adamas announce new expanded indication for Namzaric (Memantine and Donepezil Hydrochlorides) extended release for the treatment of moderate to severe Alzheimer's .disease.  Full Article

Allergan files application for approval of oculeve intranasal tear neurostimulator
Monday, 18 Jul 2016 08:05am EDT 

Allergan Plc :Allergan files application to FDA for approval of oculeve intranasal tear neurostimulator.  Full Article

Allergan spokesman says antitrust clearance is "imminent"
Wednesday, 13 Jul 2016 10:10am EDT 

: Allergan Spokesman says in emailed statement that antitrust clearance is "imminent" and agrees with Teva view that deal closing is "any time now" (Reporting By Caroline Humer) ((caroline.humer@thomsonreuters.com;)).  Full Article

Allergan, Teva deal approval expected in next 2 weeks - CNBC
Wednesday, 13 Jul 2016 09:00am EDT 

: Allergan, Teva deal approval expected in next 2 weeks - CNBC citing sources Further company coverage: [AGN.N TEVA.TA] (Bengaluru Newsroom: +1 646 223 8780).  Full Article

Photo

Amgen, Allergan apply for European nod for Avastin biosimilar

Amgen Inc and Allergan Plc said they have submitted an application to the European health regulator seeking approval of their biosimilar version of Roche Holding AG's blockbuster cancer treatment, Avastin.